Here's My Acid Test on 2 Recently Launched Psychedelics ETFs
While performance hasn't been mind blowing so far, psychedelics are where cannabis was a decade or so ago.
Keeping an Eye on 2 Cannabis Stocks Until Market Conditions Improve
I'm looking at a possible inverse head and shoulders forming on many cannabis charts.
This Isn't a Market That Can Be Easily Trusted
Yet there's good relative strength in biotech, growth, cannabis, small-caps, and other sectors that have been the biggest laggards.
To Deal With Volatility, Consider These 3 Options on the Risk Spectrum
They range from doing nothing to jumping into the day-trading fray.
Tilray Isn't Going to Get That High
TLRY posted promising earnings, but don't expect it smoke past its current levels for long.
I Wouldn't Jump on the Tilray Bandwagon, But Here's What I Would Do
You think the Tilray brand name is worth $2.8B? Market cap is barely above $3B. Does give me pause.
I'm Treading Carefully Entering 2022 as Many Momentum Stocks Remain Bearish
Cannabis is about the only space where I'm long, and that isn't for technical reasons.
2021 Year in Review: A Very Good Market for Mega-Cap Stocks... But Not Much Else
The broader market had a very tough go of it in 2021, but you wouldn't know it unless you do some digging. From Reddit and Diamond Hands to SPACs and a stealth bear market, it's been a wild ride.
Precious Metals and Cannabis Could Surprise to the Upside in 2022
And there are a few ETFs and a silver miner that could provide the vehicles to play this hunch.
With BAD and VICE ETFs, the Devil Is in the Details
Will these exchange-traded funds pay off or send your portfolio up in a 'PUF'?